Meihao Medical Group Co., Ltd

美皓醫療集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1947)

PROFIT ALERT – REDUCTION IN LOSS

This announcement is made by Meihao Medical Group Co., Ltd (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Director(s)**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that based on the information currently available to the Board and a preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended 31 December 2025 (the "**Relevant Period**"), it is expected that the Group will record a net loss ranging from approximately RMB13.1 million to approximately RMB19.8 million, as compared to the loss of approximately RMB32.6 million for the year ended 31 December 2024.

The Board considers that the decrease in loss was mainly attributable to, among others, net impact of the following factors:

(i) the scale of the Group's revenue was significantly enhanced, and the continuous expansion of business scale drove the gradual emergence of economies of scale, effectively diluting fixed costs such as depreciation and rent, thereby significantly improving overall profitability;

(ii) the significant reduction in share-based payment expenses;

(iii) the continuous optimisation of human resources allocation and personnel structure, as well as the reasonable enhancement of per capita efficiency, resulted in a steady decline in the proportion of staff remuneration to revenue, demonstrating outstanding effectiveness in human resources cost control; and

(iv) the continuous strengthening of cost control measures, continuous enhancement of internal operational efficiency, and further strict control of various operating expenses resulted in an effective decrease in operating costs and continuous optimisation of operational quality.

Regardless of the current situation, the Group still manages to keep a healthy financial position with sufficient cash reserves for the Company. The Board will continue to assess the effect of a challenging economic environment on the Group's operation and financial performance, and explore new business and profit directions. The Board believes that the short-term financial performance is only a phase and will continue to focus on expanding the business in the coming year.

At the date of this announcement, the Group is still in the process of finalising its annual results for the Relevant Period. The information contained in this announcement is only based on the preliminary assessment by the Board based on the information currently available and the unaudited consolidated financial information of the Group, which has not been confirmed or reviewed by the auditor of the Company, nor reviewed by the audit committee of the Company. Therefore, the above information may be subject to adjustment, and may differ from the audited annual results for the Relevant Period of the Group. The relevant information of the Group's performance for the Relevant Period will be disclosed in the annual results announcement to be issued by the end of March 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Meihao Medical Group Co., Ltd
Mr. Wang Xiaomin
Chairman, Chief Executive Officer and Executive Director

Wenzhou, 13 March 2026

As at the date of this announcement, the Board of the Company includes the executive Directors Mr. Wang Xiaomin and Dr. Zhou Jian; and the independent non-executive Directors Ms. Tam Hon Shan Celia, Mr. Ng Ming Chee and Mr. Zhang Yongcun.